Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
about
The mutational landscape of prostate cancerMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerCDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.Inactivation of the retinoblastoma gene yields a mouse model of malignant colorectal cancerIdentification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis.Advancing precision medicine for prostate cancer through genomics.Targeting cell cycle and hormone receptor pathways in cancer.DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness.SOX4, SOX11 and PAX6 mRNA expression was identified as a (prognostic) marker for the aggressiveness of neuroendocrine tumors of the lung by using next-generation expression analysis (NanoString).Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.A transgenic mouse model for early prostate metastasis to lymph nodes.Differential impact of RB status on E2F1 reprogramming in human cancer.Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
P2860
Q26851631-4139B66F-0F45-4E1D-B7AA-CAADB7F089C8Q27024775-65077C9D-5E5A-4ACA-A456-795A8048688CQ36130084-3CD56D65-92D6-4A36-900E-43D8E4210345Q36344583-28E8F3FD-128E-44C7-A6D1-F1C678DF3EA8Q36413013-3DD8DD57-BBAC-41CC-922E-02B22A89C33AQ37255151-E42B0310-8574-406E-8CCC-AC14F164D14EQ37502364-C885D4F5-4757-4E1E-92B7-590CB2827041Q38893748-7C9CF609-7EEC-4105-9DDB-72A4931085FBQ38962238-325CC51D-F109-4AC4-9959-5B5180ED9EE7Q39025929-830E2ED5-5BEC-4683-8BA6-453C0D04370BQ39044979-A155808A-1174-4E56-8A67-175866861894Q39124486-3317230A-181C-448A-B14B-4B43B81F499EQ41864582-3B859C80-3E0A-4B25-BE5C-9F4BD5CD3430Q46068832-8370D7FB-44B4-4B6A-BB2A-F34697146681Q47158122-A808677F-3ADB-4CE1-8785-8EE2A46AF9B7Q47234339-3C800610-604B-4768-B14E-92FEC5DA6379
P2860
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@en
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@nl
type
label
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@en
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@nl
prefLabel
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@en
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@nl
P2860
P356
P1476
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.
@en
P2093
Ana Aparicio
P2860
P2888
P304
P356
10.1038/NRUROL.2011.107
P407
P577
2011-08-02T00:00:00Z